In a striking policy shift, President Donald Trump has emerged as an unlikely but powerful advocate for the U.S. cannabis industry. Through executive action and swift implementation by his administration, Trump has delivered meaningful federal reforms that many in the sector have long sought, particularly around medical marijuana. While not amounting to full legalization, these changes could reshape the multibillion-dollar industry by easing tax burdens and unlocking new opportunities for growth.
A Historic Executive Order
On December 18, 2025, President Trump signed an executive order titled “Increasing Medical Marijuana and Cannabidiol Research.” The directive instructed the Department of Justice and Drug Enforcement Administration to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move recognizes the drug’s accepted medical uses, lowers its perceived risk profile, and aims to expand scientific research while improving patient access.
The administration followed through rapidly. On April 23, 2026, Acting Attorney General Todd Blanche signed an order immediately placing FDA-approved cannabis products and those regulated under qualifying state medical marijuana licenses into Schedule III. A broader administrative hearing process for comprehensive rescheduling began in late June 2026.
Trump has framed the changes around compassion and research, highlighting benefits for patients dealing with chronic pain, cancer, seizures, and veterans’ service-related conditions. He has emphasized that the policy does not legalize recreational marijuana federally but focuses on medical applications and states’ rights.
Major Tax Relief and Economic Impact
One of the most transformative elements is relief from Internal Revenue Code Section 280E, which previously barred cannabis businesses from deducting ordinary expenses like rent, payroll, and marketing. This led to effective tax rates as high as 70% or more on gross revenue.
Under Schedule III status, qualifying medical marijuana operators can now claim standard business deductions, potentially slashing their tax liabilities dramatically. The Treasury Department is even considering retroactive relief, which could result in significant refunds for companies that have paid billions in recent years. Publicly traded firms such as Trulieve and Curaleaf stand to benefit substantially.
The legal cannabis market, valued at around $30 billion in 2025 and projected to exceed $47 billion in 2026, has faced chronic challenges including high compliance costs, limited banking access, and investor hesitation. These federal steps could attract new capital, talent, and legitimacy to the sector.
Industry Reactions and Key Players
Cannabis executives and advocates have largely welcomed the developments. Trulieve CEO Kim Rivers, often described as the industry’s “Trump whisperer,” played a notable role in lobbying efforts alongside figures like longtime Trump associate Howard Kessler. Rivers and others have praised the administration for delivering on promises to support research and reduce regulatory burdens.
Stakeholders highlight potential benefits including expanded research, better consumer protections, and a more stable business environment. However, some note that the changes are partial—primarily benefiting pure medical operators—leaving recreational and mixed businesses navigating ongoing complexities.
Remaining Challenges and Outlook
Despite the progress, federal prohibition on recreational cannabis remains intact. Interstate commerce is still restricted, and full banking reform or comprehensive legalization would require congressional action. Implementation details, such as IRS guidance and the scope of retroactive tax relief, will determine the depth of the impact.
Trump’s approach reflects a pragmatic blend of states’ rights, medical innovation, and economic opportunity. For an industry long marginalized by federal policy, his administration’s actions mark a turning point that could accelerate mainstream acceptance and commercial success.
As the cannabis sector continues to mature, the coming months—shaped by hearings, regulatory guidance, and potential further reforms—will reveal whether President Trump’s support solidifies his role as the industry’s new best friend. For now, many operators are optimistic about a brighter, more profitable future.
About The Author
